Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Depreciation & Amortization (CF): 2010-2025

Historic Depreciation & Amortization (CF) for Amicus Therapeutics (FOLD) over the last 15 years, with Sep 2025 value amounting to $1.9 million.

  • Amicus Therapeutics' Depreciation & Amortization (CF) fell 13.64% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.6 million, marking a year-over-year decrease of 12.48%. This contributed to the annual value of $8.5 million for FY2024, which is 8.56% up from last year.
  • Amicus Therapeutics' Depreciation & Amortization (CF) amounted to $1.9 million in Q3 2025, which was up 1.19% from $1.9 million recorded in Q2 2025.
  • Over the past 5 years, Amicus Therapeutics' Depreciation & Amortization (CF) peaked at $2.2 million during Q3 2023, and registered a low of $1.3 million during Q1 2023.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $2.2 million (2024), whereas its average is $2.0 million.
  • In the last 5 years, Amicus Therapeutics' Depreciation & Amortization (CF) tumbled by 40.40% in 2021 and then soared by 73.25% in 2023.
  • Amicus Therapeutics' Depreciation & Amortization (CF) (Quarterly) stood at $1.5 million in 2021, then decreased by 13.64% to $1.3 million in 2022, then surged by 66.44% to $2.2 million in 2023, then declined by 6.46% to $2.0 million in 2024, then declined by 13.64% to $1.9 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $1.9 million for Q3 2025, versus $1.9 million for Q2 2025 and $1.8 million for Q1 2025.